在肝硬化中均的肝内门氨分布
Carsten Meyer1, Olga Ramig1, Narine Mesropyan1
1Department of Diagnostic and Interventional Radiology and Quantitative Imaging Lab Bonn (QILaB), University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Scientific reports
|October 1, 2025
概括
经过横性肝内移植系统分流 (TIPS) 后的肝脑病变 (HE) 发生率可能不是由于门静脉分支中的氨差异. 在肝硬化患者的右门静脉和左门静脉中,氨水平相似.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 干预性放射学 干预性放射学
- 胃肠病学 胃肠病学
背景情况:
- 跨内肝移植系统分流 (TIPS) 放置是一种常见的程序,用于管理门性高血压的并发症.
- 肝脑病变 (HE) 是TIPS后的一个已知的并发症,一些研究表明左侧分流布置的发病率较低.
- 较低的HE率的一个假设原因是门静脉系统中的氨分布差异.
研究的目的:
- 在TIPS植入之前,研究各种部和门静脉部位的氨度.
- 要确定右侧和左侧门静脉分支中的氨分布是否有显著差异.
- 评估氨水平与TIPS后的潜在高等教育发展之间的关系.
主要方法:
- 一项前性研究,涉及50名正在接受TIPS的禁食性肝硬化患者.
- 在五个静脉部位测量氨度:上层中枢静脉,脏静脉,右门静脉和左门静脉.
- 不同静脉部位和门静脉分支之间的氨水平的比较.
主要成果:
- 氨的含量在上层中枢静脉 (143μg/dl) 与脏静脉 (66μg/dl) 相比显著更高.
- 右侧 (104μg/dl) 和左侧 (107μg/dl) 门静脉分支中的平均氨度相当.
- 在右侧和左侧门静脉分支之间没有观察到氨水平的系统差异.
结论:
- 在禁食性肝炎患者中,门静脉主要分支中的氨水平并没有显著差异.
- 与TIPS安置地点相关的HE率观察到的差异不太可能是由于门脉中局部氨分布.
- 需要进一步的研究来探索促进TIPS之后的高等教育发展的替代机制.
相关概念视频
Hepatic Portal System
5.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.3K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
214
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
214
Urea Cycle
49.7K
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
49.7K


